Xylem Polarimeters Measure Chiral Compounds
The ADP600 Series high accuracy Peltier temperature-controlled polarimeters from Xylem?s Bellingham + Stanley brand measure chiral compounds and other optically active substances.
The ADP600 Series high accuracy Peltier temperature-controlled polarimeters from Xylem’s Bellingham + Stanley brand measure chiral compounds and other optically active substances. The polarimeters are available as single, dual, and multiple wavelength derivatives covering the visible spectrum and the ultraviolet region. ADP600 polarimeters have an extensive interfacing capability and may be configured to operate in secure environments in accordance with FDA regulation 21 CFR Part 11 and also meet the requirements of US, European, and Japanese pharmacopeia. A full-color, high-definition touchscreen graphical user interface simplifies operation. A full range of accessories is available including low-volume, standard, and flow-through sample tubes as well as United Kingdom Accreditation Service-certified, quartz control plates.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Hesperos, Psilera Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.
